Foster Dykema Cabot & Partners LLC Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Foster Dykema Cabot & Partners LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1,078.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 884 shares of the company’s stock after purchasing an additional 809 shares during the quarter. Foster Dykema Cabot & Partners LLC’s holdings in IDEXX Laboratories were worth $365,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in IDXX. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $29,000. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories during the 4th quarter valued at about $30,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $31,000. Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth about $38,000. Finally, Crews Bank & Trust acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $41,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research reports. Bank of America increased their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a report on Monday. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Finally, Barclays boosted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $523.75.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $402.38 on Thursday. The firm has a market cap of $32.61 billion, a PE ratio of 37.71, a P/E/G ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business has a 50-day moving average price of $424.47 and a 200 day moving average price of $432.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.